Improving personalized treatment with alpha particle radiation for cancer
Official title: Macro-to-micro (M2µ) Activity Apportionment for αRPT
Funded at Johns Hopkins University · NIH-10931448 · Data updated 2026-11-12
This study is looking at a new way to improve cancer treatment with special radiation by measuring how it spreads in the body, so doctors can give each patient a more personalized and effective therapy while minimizing side effects.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $473,956 |
| NIH project number | 5P01CA272222-02 |
| Project ID | NIH-10931448 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with bone metastases or other cancers that may benefit from alpha particle radiopharmaceutical therapies.
✕Less likely to help
Patients who do not have cancers treatable with alpha particle radiation or those who are not eligible for radiopharmaceutical therapies may not benefit from this research.
What this research studies
This research focuses on enhancing the delivery of alpha particle radiopharmaceuticals (αRPTs) for cancer treatment by developing a new dosimetric methodology called Macro-to-micro (M2µ). The goal is to create a more personalized approach to treatment by accurately measuring the distribution of radiation in specific organs and tissues, which can help tailor therapy to individual patients. By using murine models, the researchers will assess how radiation is absorbed in different organ regions, aiming to improve treatment outcomes and reduce side effects. This innovative approach seeks to address current limitations in dosimetry that affect the effectiveness and safety of αRPTs.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments with fewer side effects for patients receiving alpha particle radiation therapy.
How similar studies have gone: Other research has shown promise in the use of targeted alpha particle therapies, but the specific Macro-to-micro methodology is a novel approach that has not been extensively tested.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Hobbs, Robert Francois — Johns Hopkins University
- Study coordinator: Hobbs, Robert Francois
Related research
Other NIH-funded projects on the same topics.
-
Targeting hidden brain injuries in iTTP to improve long-term brain health
A researcher aims to find out how silent brain injuries in people with immune thrombotic thrombocytopenic purpura (iTTP) happen, how they affect thinking and stroke risk, and how to prevent them.
-
Accelerated flap coverage for severe leg injuries: earlier reconstruction vs standard timing
This study tests whether doing early flap coverage after a severe leg injury lowers infection risk and improves healing for patients with open wounds and bone injury.
-
Placebo-controlled shunting for iNPH: does the surgery help with walking and balance?
A doctor-led trial at Johns Hopkins will test whether a shunt surgery improves walking and balance in older adults with idiopathic normal pressure hydrocephalus.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
Johns Hopkins Total Worker Health Center focusing on mental health
A nationwide center at Johns Hopkins is working to improve mental health and well-being among workers by studying workplace health strategies and translating findings into practical tools.
-
Role of fat droplets in liver fat and inflammatory signals in NAFLD
A study at Johns Hopkins will explore how fat droplets in the liver influence molecules that drive inflammation and progression of non-alcoholic fatty liver disease (NAFLD) in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.